Spero Therapeutics to Present at Two Upcoming November Conferences

Spero Therapeutics to Present at Two Upcoming November Conferences

November 10, 2016

CAMBRIDGE, Mass, November 10, 2016 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that Ankit Mahadevia, President and CEO, will present a corporate overview at the following upcoming conferences.

• Stifel 2016 Healthcare Conference on November 16, 2016 at 9:30 a.m. ET in New York, NY
• Piper Jaffray 28th Annual Healthcare Conference on November 29, 2016 at 10:10 a.m. ET in New York, NY

About Spero

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company’s pipeline of anti-infective agents is one of the most unique in the industry. The Spero Potentiator program provides the opportunity to increase the power of standard of care by enhancing existing drugs through a dramatic increase in their potency against multi-drug resistant gram-negative bacteria. Spero recently received an award from the Department of Defense to help fund the Potentiator program. The DHFR program is exploring a new approach to combatting drug resistance through expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim- resistant Gram-negative bacteria. In September 2016, Spero joined the ENABLE (European Gram-negative Antibacterial Engine) project, which provides non-dilutive resources for the development of the DHFR program.

Spero’s pipeline of drug candidates may uniquely reduce the morbidity caused by severe infections and promote their clearance, including in bacterial strains highly resistant to even the most potent existing antibiotics. For more information, please visit https://sperotherapeutics.com.

MEDIA CONTACT:
Spectrum Science Communications:
Maia Arnold, PhD
Senior Scientific Executive
202-955-6222 x2506
marnold@spectrumscience.com

INVESTOR CONTACT:
Stern Investor Relations
Beth DelGiacco, Vice President
212-362-1200
Beth@sternir.com